Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
LRMR

LRMR - Larimar Therapeutics, Inc. Stock Price, Fair Value and News

7.27USD-0.86 (-10.58%)Market Closed

Market Summary

LRMR
USD7.27-0.86
Market Closed
-10.58%

LRMR Alerts

  • 1 major insider buys recently.

LRMR Stock Price

View Fullscreen

LRMR RSI Chart

LRMR Valuation

Market Cap

463.8M

Price/Earnings (Trailing)

-10.29

Price/Sales (Trailing)

222.35

Price/Free Cashflow

-12.71

LRMR Price/Sales (Trailing)

LRMR Profitability

Return on Equity

-19.53%

Return on Assets

-18.16%

Free Cashflow Yield

-7.87%

LRMR Fundamentals

LRMR Revenue

Revenue (TTM)

2.3M

LRMR Earnings

Earnings (TTM)

-45.1M

Earnings Growth (Yr)

-124.55%

Earnings Growth (Qtr)

-12.78%

Breaking Down LRMR Revenue

Last 7 days

-9.0%

Last 30 days

2.7%

Last 90 days

1.0%

Trailing 12 Months

119.6%

How does LRMR drawdown profile look like?

LRMR Financial Health

Current Ratio

17.99

LRMR Investor Care

Shares Dilution (1Y)

47.45%

Diluted EPS (TTM)

-0.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20192.3M000
20181.0M1.1M1.5M1.9M
2017912.0K934.0K970.0K996.0K
2016608.0K770.0K857.0K894.0K
2015130.5K233.0K335.5K438.0K
201400028.0K

Tracking the Latest Insider Buys and Sells of Larimar Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 16, 2024
hamilton thomas edward
bought
499,998
8.74
57,208
-
Feb 16, 2024
flynn james e
bought
12,500,000
8.74
1,430,200
-
Feb 16, 2024
flynn james e
bought
12,500,000
8.74
1,430,210
-
Feb 14, 2024
thomas frank e
bought
22,000
11.00
2,000
-
Jan 17, 2024
shankar gopi
acquired
-
-
22,500
chief development officer
Jan 17, 2024
clayton russell
acquired
-
-
22,500
chief medical officer
Jan 17, 2024
ben-maimon carole
acquired
-
-
66,125
president and ceo
Jan 17, 2024
celano michael
acquired
-
-
31,250
chief financial officer
Dec 07, 2023
shankar gopi
bought
18,661
3.7323
5,000
chief development officer

1–10 of 26

Which funds bought or sold LRMR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 29, 2024
Opaleye Management Inc.
reduced
-72.03
-1,513,130
1,323,800
0.29%
May 20, 2024
Virtu Financial LLC
new
-
133,000
133,000
0.01%
May 17, 2024
Aspect Partners, LLC
new
-
7,590
7,590
0.01%
May 17, 2024
Ikarian Capital, LLC
reduced
-27.26
585,377
3,328,430
0.36%
May 16, 2024
COMERICA BANK
new
-
3,150
3,150
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.00
657
19,863
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
294,681
294,681
-%
May 15, 2024
Cubist Systematic Strategies, LLC
new
-
167,640
167,640
-%
May 15, 2024
DEUTSCHE BANK AG\
reduced
-0.16
824,606
2,063,900
-%
May 15, 2024
Driehaus Capital Management LLC
new
-
8,259,640
8,259,640
0.08%

1–10 of 44

Are Funds Buying or Selling LRMR?

Are funds buying LRMR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LRMR
No. of Funds

Unveiling Larimar Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 15, 2024
flynn james e
9.64%
6,151,389
SC 13D/A
Feb 26, 2024
ra capital management, l.p.
9.5%
6,045,351
SC 13G
Feb 16, 2024
flynn james e
10.07%
6,151,389
SC 13D/A
Feb 15, 2024
flynn james e
10.75%
4,721,183
SC 13D/A
Feb 14, 2024
blue owl capital holdings lp
7.78%
3,414,468
SC 13G
Feb 14, 2024
verition fund management llc
6.4%
2,811,131
SC 13G
Feb 14, 2024
perceptive advisors llc
0%
0
SC 13G/A
Feb 13, 2024
janus henderson group plc
6.0%
2,641,065
SC 13G/A
Aug 18, 2023
janus henderson group plc
5.1%
2,191,411
SC 13G
Mar 17, 2023
flynn james e
10.91%
4,721,183
SC 13D/A

Recent SEC filings of Larimar Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 10, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
8-K
Current Report
May 30, 2024
8-K
Current Report
May 24, 2024
EFFECT
EFFECT

Peers (Alternatives to Larimar Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-17.75% 15.65%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
50.83% 15.66%
-84.89
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
12.78% -8.91%
78.71
6.54
13.74% 186.89%
14.3B
3.8B
11.22% 2.07%
19.2
3.8
8.58% 129.81%
MID-CAP
4.7B
524.1M
-5.39% -54.95%
-11.17
8.9
394.93% 39.61%
4.3B
107.9M
-17.68% 46.87%
-7.87
48.09
54.84% -28.31%
3.7B
251.0M
4.40% -10.91%
-12.58
14.85
73.58% -86.73%
3.4B
240.7M
9.49% -22.70%
-7.15
12.77
-1.03% -213.92%
2.6B
813.8M
4.41% -35.25%
-1.5K
3.22
56.43% 98.83%
2.0B
996.6M
-9.61% 109.10%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.09% 16.96%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-3.44% 394.54%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-27.55% 54.46%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-4.57% 211.94%
-0.78
7.61
-13.45% 69.54%

Larimar Therapeutics, Inc. News

Latest updates
MarketBeat21 Jun 202408:42 pm
MarketBeat17 Jun 202409:56 pm

Larimar Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q42016Q32016Q22016Q12015Q42015Q32015Q22015Q12014Q42014Q32014Q2
Revenue-4.9%64267562332426725626624722723023022520919314363.0039.0026.0014.001.00
Operating Expenses-9.6%13,27714,69115,16915,560----------------
  S&GA Expenses12.7%3,6463,2343,3393,351----------------
  R&D Expenses-15.9%9,63111,45711,83012,209----------------
EBITDA Margin0.1%-61.27*-61.31*------------------
Interest Expenses0.2%5004994754664588.0031.0053.0073.0097.00132140160180200213213212213443
EBT Margin0%-63.27*-63.27*------------------
Net Income67.6%-4,724-14,570-15,067-15,775----------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets158.7%24896.0010411211912613363.0071.0079.0088.0081.0093.0010511412574.0083.0093.00104110
  Current Assets156.1%23190.0098.0010611312112757.0065.0072.0081.0074.0086.0098.0010811965.005.0083.0094.00107
    Cash Equivalents311.7%11027.0039.0094.0011227.0086.0020.0063.0070.0072.0071.0062.0068.0010111339.001.0043.0037.0036.00
  Net PPE-11.7%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.000.001.001.000.00
Liabilities22.1%17.0014.0011.0012.0013.0016.0014.0013.0014.0014.0016.0013.0014.0015.0011.0013.0023.006.0033.0032.0028.00
  Current Liabilities35.1%13.0010.007.007.008.0011.009.008.009.009.0010.008.008.009.005.007.0010.006.0016.0013.0014.00
Shareholder's Equity182.5%23182.0093.0010010611111950.0057.0064.0072.0068.0079.0090.001031132.0054.002.001.001.00
  Retained Earnings-7.8%-203-188-175-166-158-151-142-133-125-116-107-90.31-77.70-65.61-51.41-41.14-399-23.13-389-376-364
  Additional Paid-In Capital60.7%43427026826626426226118418218117915815615515415445122.00449448446
Shares Outstanding45.3%64.0044.0044.0043.0044.0043.0020.0018.0018.0018.0018.0016.00---------
Float----80,219---21.00---94.00---123---40.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-11.4%-10,411-9,343-9,200-7,365-7,551-6,672-5,878-7,486-7,533-7,918-12,199-10,782-11,206-9,857-11,222-12,199-8,921-7,911-5,8233,506-12,471
  Share Based Compensation10.9%2,1281,9181,8212,0431,8331,6431,6661,6751,6351,4801,4631,3501,1801,01069610029.0029.00-1,0211002,076
Cashflow From Investing-2500.4%-68,364-2,629-46,430-9,83892,250-52,234-3,384--6,490-6,79119,2195,251-23,545-8.0041,421-778-50.00--840807
Cashflow From Financing-162,151-----316-------242-13583,9039,5773,4559,9505,89595.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LRMR Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 12,939$ 4,562
General and administrative3,7953,075
Total operating expenses16,7347,637
Loss from operations(16,734)(7,637)
Other income net2,0801,111
Net loss$ (14,654)$ (6,526)
Net loss per share, basic$ (0.27)$ (0.15)
Net loss per share, diluted$ (0.27)$ (0.15)
Weighted average common shares outstanding, basic53,553,70743,897,603
Weighted average common shares outstanding, diluted53,553,70743,897,603
Comprehensive loss:  
Net loss$ (14,654)$ (6,526)
Other comprehensive gain (loss):  
Unrealized gain (loss) on marketable securities(106)31
Total other comprehensive gain (loss)(106)31
Total comprehensive loss$ (14,760)$ (6,495)

LRMR Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 110,125$ 26,749
Short-term marketable securities117,17160,041
Prepaid expenses and other current assets3,6573,385
Total current assets230,95390,175
Long-term marketable securities11,711 
Property and equipment, net604684
Operating lease right-of-use assets2,9203,078
Restricted cash1,3391,339
Other assets678659
Total assets248,20595,935
Current liabilities:  
Accounts payable1,9181,283
Accrued expenses10,0987,386
Operating lease liabilities, current825837
Total current liabilities12,8419,506
Operating lease liabilities4,5204,709
Total liabilities17,36114,215
Commitments and contingencies (See Note 8)
Stockholders’ equity:  
Common stock, $0.001 par value per share; 115,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 63,800,017 and 43,909,069 shares issued and outstanding as of March 31, 2024 and December 31, 20236443
Additional paid-in capital434,013270,150
Accumulated deficit(203,208)(188,554)
Accumulated other comprehensive gain (loss)(25)81
Total stockholders’ equity230,84481,720
Total liabilities and stockholders’ equity$ 248,205$ 95,935
LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
 CEO
 WEBSITElarimartx.com
 INDUSTRYBiotechnology
 EMPLOYEES26

Larimar Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Larimar Therapeutics, Inc.? What does LRMR stand for in stocks?

LRMR is the stock ticker symbol of Larimar Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Larimar Therapeutics, Inc. (LRMR)?

As of Mon Jun 24 2024, market cap of Larimar Therapeutics, Inc. is 463.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LRMR stock?

You can check LRMR's fair value in chart for subscribers.

What is the fair value of LRMR stock?

You can check LRMR's fair value in chart for subscribers. The fair value of Larimar Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Larimar Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LRMR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Larimar Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether LRMR is over valued or under valued. Whether Larimar Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Larimar Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LRMR.

What is Larimar Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jun 24 2024, LRMR's PE ratio (Price to Earnings) is -10.29 and Price to Sales (PS) ratio is 222.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LRMR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Larimar Therapeutics, Inc.'s stock?

In the past 10 years, Larimar Therapeutics, Inc. has provided -0.095 (multiply by 100 for percentage) rate of return.